RxDoctor Payments Data

John Rabets, MD

Transplant Surgery · Toledo, OHNPI 1174749907

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $677 of the $910 with a category attached, or 74.4%. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 39.3% of the total. Reporting peaked in 2023 at $436 and has fallen 87.4% since, to $55 in 2025. That places this record below the midpoint for transplant surgery clinicians in OH, where the typical reported total is $1,754.

$910in general payments, 2019–2025

Across 16 payments — averaging $56.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$358
  • Olympus America Inc.$173
  • Angiodynamics, Inc.$141
  • Axonics, Inc.$72
  • Convatec Inc.$60
  • AbbVie$58
  • plus $48 from 2 others

What the payments were for

  • Food & beverage$67774%
  • Education$23326%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$910 in reported general payments places this provider in the 40th percentile of 43 transplant surgery providers in Ohio.

See all transplant surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$89,706
Medicare patients
174
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron48$24,278
Valganciclovir Hcl97$15,480
Clotrimazole130$6,630
Envarsus XrTacrolimus14$6,082
Tamsulosin Hcl214$2,281
Methenamine Hippurate58$2,269
Oxybutynin Chloride ErOxybutynin Chloride153$2,176
Tacrolimus12$1,018
Finasteride140$890
Nifedipine ErNifedipine27$882
Prednisone139$846
Famotidine99$747
Dapsone12$460
Gabapentin30$431
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim146$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$358$24,27848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 43 transplant surgery providers in Ohio.

Other transplant surgery in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →